Share

June 2015; 1 (1) ArticleOpen Access

Epileptic encephalopathy-causing mutations in DNM1 impair synaptic vesicle endocytosis

Ryan S. Dhindsa, Shelton S. Bradrick, Xiaodi Yao, Erin L. Heinzen, Slave Petrovski, Brian J. Krueger, Michael R. Johnson, Wayne N. Frankel, Steven Petrou, Rebecca M. Boumil, David B. Goldstein
First published April 17, 2015, DOI: https://doi.org/10.1212/01.NXG.0000464295.65736.da
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1453

Share

Article Information

vol. 1 no. 1 e4
DOI: 
https://doi.org/10.1212/01.NXG.0000464295.65736.da
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • Received March 1, 2015
  • Accepted in final form March 20, 2015
  • First Published April 17, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Ryan S. Dhindsa,
    2. Shelton S. Bradrick, PhD,
    3. Xiaodi Yao, PhD,
    4. Erin L. Heinzen, PharmD, PhD,
    5. Slave Petrovski, PhD,
    6. Brian J. Krueger, PhD,
    7. Michael R. Johnson, DPhil,
    8. Wayne N. Frankel, PhD,
    9. Steven Petrou, PhD,
    10. Rebecca M. Boumil, PhD and
    11. David B. Goldstein, PhD
  1. Ryan S. Dhindsa,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Shelton S. Bradrick, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Xiaodi Yao, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Erin L. Heinzen, PharmD, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health, 1R01NS089552-01, 09/01/11-07/31/16 National Institutes of Health, 5U01-NS077303-03, 09/01/11-07/31/16 National Institutes of Health, 5R21-NS078657-02, 03/01/12-12/31/15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. CURE AHC, no grant number, Multi-electrode array screening for Candidate Drugs in ATP1A3 Mutations D801N & E815K., 08/01/14-07/31/15 CURE, no grant number. Epilepsy Genome Initiative, 2013-present

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Slave Petrovski, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Brian J. Krueger, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Commercial - LabCorp - Genomics Technology Consulting Commercial - GLG - Genomics Technology Consulting

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Michael R. Johnson, DPhil,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Patent pending for potential new drug target in epilepsy (see Johnson et al., Nature Communications 2015)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Wayne N. Frankel, PhD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R37 NS031348. 2014-2017

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Steven Petrou, PhD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 2014 Pharmacodynamic analysis of Fluvax for prediction of potential liability. CSL. Petrou S. $26K

    Research Support, Government Entities:

    1. 2014-2015 Precision medicine at the Australian Ion Channel Analysis Facility. Therapeutic Innovation Australia (NCRIS). Petrou S. $70K 2014-2021 ARC Centre of Excellence for Integrative Brain Function (CIBF). $12,000,000 2011 – 2015 Neurobiology of Human Epilepsy: Genes, Cellular Mechanisms, Networks and Whole Brain; NHMRC Program Grant Chief Investigator. $14,000,000. 2013 – 2015 Glucose Homeostasis in Epilepsy; NHMRC Project Grant. Petrou S, Reid CA and Mullen SA. $300K. 2010 – 2015 How Gene Mutations Cause Epilepsy, NHMRC Senior Research Fellowship Level B. Petrou S. $580K 2012 – 2014 Brain Sodium Channel: Functional Role of Developmentally Regulated Alternative Splicing, Australian Research Council (ARC) Discovery Project. Petrou S and Reid CA. $300K 2012 – 2014 Genetic Dissection of Functional-Structural Connectivity using Optogenetic fMRI and dMRI Tractography, ARC Discovery Project. Petrou S, Calamente F and Reid CA. $300K

    Research Support, Academic Entities:

    1. 2014 Interdisciplinary Seed Grant (UoM). Petrou S, Ordidge RA, Palmer L, Skafidas S. $19K

    Research Support, Foundations and Societies:

    1. 2014 DHB foundation. Brain in a dish modeling for neurogenetic disorders. Petrou S. $238K 2014 Macquarie Bank. Genome edited disease in a dish models for neurogenetic disorders. Petrou S. $30K

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Rebecca M. Boumil, PhD and
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH, R01NS073576, PI, 4 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. David B. Goldstein, PhD
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Molecular Genetics and Microbiology (S.S.B.), Duke University School of Medicine (R.S.D., S.S.B., X.Y.), Durham, NC; Institute for Genomic Medicine (E.L.H., S.P., B.J.K., D.B.G.), Columbia University, New York, NY; Department of Medicine (S. Petrovski), The University of Melbourne, Austin Health and Royal Melbourne Hospital, Melbourne, Australia; Centre for Clinical Translation (M.R.J.), Division of Brain Sciences, Imperial College London, Charing Cross Hospital Campus, London, United Kingdom; The Jackson Laboratory (W.N.F., R.M.B.), Bar Harbor, ME; and Division of Epilepsy (S. Petrou), The Florey Institute of Neuroscience, Victoria, Australia.
  1. Correspondence to Dr. Goldstein: dg2875{at}cumc.columbia.edu
View Full Text

Article usage

Article usage: April 2015 to August 2023

AbstractFullPdfSource
Apr 201527435241Highwire
May 201546730944Highwire
Jun 201528519829Highwire
Jul 20154478056Highwire
Aug 20151555316Highwire
Sep 2015961425Highwire
Oct 20151051025Highwire
Nov 2015774714Highwire
Dec 201565629Highwire
Jan 2016691518Highwire
Feb 20161001123Highwire
Mar 2016783335Highwire
Apr 20161011120Highwire
May 2016772411Highwire
Jun 2016651214Highwire
Jul 2016661123Highwire
Aug 20168299Highwire
Sep 2016118718Highwire
Oct 201694133Highwire
Nov 2016912212Highwire
Dec 2016807216Highwire
Jan 2017652168Highwire
Feb 2017511474Highwire
Mar 2017722059Highwire
Apr 2017601037Highwire
May 2017341308Highwire
Jun 2017239518Highwire
Jul 201730957Highwire
Aug 2017191075Highwire
Sep 2017221129Highwire
Oct 2017351809Highwire
Nov 2017472839Highwire
Dec 20179843Highwire
Jan 2018136211Highwire
Feb 201815448Highwire
Mar 20188449Highwire
Apr 201827757Highwire
May 2018251586Highwire
Jun 2018231868Highwire
Jul 2018131347Highwire
Aug 2018211009Highwire
Sep 2018209710Highwire
Oct 20182525119Highwire
Nov 20181428322Highwire
Dec 20181238513Highwire
Jan 20191045614Highwire
Feb 20191830017Highwire
Mar 20191315734Highwire
Apr 20192114117Highwire
May 20191610817Highwire
Jun 20191111824Highwire
Jul 20191712510Highwire
Aug 20191211821Highwire
Sep 20191210111Highwire
Oct 2019161118Highwire
Nov 20191311325Highwire
Dec 201991067Highwire
Jan 20201436612Highwire
Feb 2020482719Highwire
Mar 20201298413Highwire
Apr 2020776915Highwire
May 2020129529Highwire
Jun 2020730317Highwire
Jul 20205609Highwire
Aug 2020135810Highwire
Sep 20201524113Highwire
Oct 20201012311Highwire
Nov 2020164612Highwire
Dec 2020134110Highwire
Jan 2021164618Highwire
Feb 2021184612Highwire
Mar 202116569Highwire
Apr 202113418Highwire
May 202114389Highwire
Jun 2021274610Highwire
Jul 2021174510Highwire
Aug 2021173911Highwire
Sep 202113579Highwire
Oct 2021256627Highwire
Nov 2021132920Highwire
Dec 2021113011Highwire
Jan 2022162413Highwire
Feb 202223549Highwire
Mar 2022295119Highwire
Apr 202219409Highwire
May 2022244910Highwire
Jun 202221377Highwire
Jul 2022241493Highwire
Aug 2022442109Highwire
Sep 20223215814Highwire
Oct 202225587Highwire
Nov 20223510225Highwire
Dec 2022263910Highwire
Jan 20231411912Highwire
Feb 20238359Highwire
Mar 2023332912Highwire
Apr 202391812Highwire
May 2023243321Highwire
Jun 202316314Highwire
Jul 2023163321Highwire
Aug 2023134012Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Alert Me

Recommended articles